Blood Glucose in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation

Recruiting now

Conditions studied: Preterm Birth, Hyperglycemia, Neonatal Hypoglycemia, Threatened Preterm Labor

In brief

In case of threatening preterm birth, it is standard to recommend treatment with betamethasone to accelerate fetal lung maturation. In pregnant women with diabetes, treatment with betamethasone can lead to significant hyperglycemia, which may cause hypoglycemia in the neonate. Changes in blood glucose in non-diabetic women are less investigated. In this study we aim to examine changes in maternal blood glucose levels in non-diabetic women, during treatment with betamethasone, by continuous glucose monitoring. Hypotheses: Administration of betamethasone induce significant hyperglycemia in non-diabetic pregnant women during treatment.

Key facts

Study ID

NCT06794307

Run by

University of Aarhus

People needed

25

Starts

2024-11-20

Expected to finish

2026-01-01

Last updated by the study team

2025-01-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Pregnant in gestational week 24+0 - 34+0 admitted with symptoms of threatened preterm birth:
• Premature contractions and shortening of the cervix, or
• Preterm premature rupture of membranes.
• Treatment with betamethasone for fetal lung maturation is planned, or started (maximum 4 hours before inclusion)
• Age over 18 years
• Read and understand Danish

You may not qualify if…

• Multiple pregnancy
• Diabetes
• Pre-existing maternal use of medications that affect glucose metabolism

Where it is running

• Aarhus University Hospital — Aarhus, Central Region Denmark, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.